IOMX
Live / Applied — Non-final action mailed (as of 27 Feb 2026)
What this means for you
Not registered yet, but its 18 Dec 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79419666
- Mark type
- Stylized text
- Filed
- 18 Dec 2024
- Attorney of record
- Alisa C. Simmons
Goods and services
- Class 001 — Chemicals: Chemical preparations for scientific and general industrial manufacturing purposes; Biochemical preparations, namely, genetically engineered polypeptides, for scientific purposes and proteins in raw material form for scientific and medical research, in particular antibodies and antibody-like polypeptides and proteins, and nucleic acid coding sequences for these for scientific purposes, in particular artificial polypeptides and proteins and nucleic acid coding sequences for these for scientific purposes; diagnostic preparations, except for medical or veterinary use.
- Class 005 — Pharmaceuticals: Pharmaceutical diagnostic medical and veterinary preparations; pharmaceutical preparations and formulations and medicinal health preparations for use in the treatment or prevention of diseases, ailments and/or disorders in humans and/or animals, in particular circulatory, respiratory, endocrine, neurological, cardiovascular, nutritional, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, ailments and/or disorders and the treatment or prevention of complications associated with such diseases, ailments and/or disorders; pharmaceutical preparations and formulations and medicinal health preparations for use in the treatment or prevention of illnesses, ailments and/or disorders in humans and/or animals, in particular bone, sensory organ, viral, urinary tract, kidney, metabolic or central nervous system diseases, complaints and/or disorders and the treatment or prevention of complications associated with such diseases, ailments and/or disorders; pharmaceutical preparations and formulations and medicinal health preparations for use in the treatment or prevention of diseases, ailments and/or disorders in humans and/or animals, in particular infectious, autoimmune or immunological, cell proliferative and/or oncological diseases, ailments and/or disorders, cancers, tumours and metastases and the treatment or prevention of complications associated with such diseases, ailments and/or disorders; pharmaceutical preparations and formulations and medical health preparations, in particular artificial polypeptides and proteins, in particular antibodies and antibody-like polypeptides and proteins, and nucleic acid coding for these, in particular for use in the following areas: treatment or prevention of various types of cancer, inflammatory diseases and autoimmune diseases; diagnostic preparations and biomarker reagents for medical or veterinary purposes; diagnostic preparations and diagnostic biomarker reagents for the diagnosis and/or prognosis of human and/or animal diseases, ailments and/or disorders, in particular circulatory, respiratory, endocrine, neurological, cardiovascular, nutritional, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, ailments and/or disorders and the diagnosis and/or prognosis in relation to complications associated with such diseases, ailments and/or disorders; diagnostic preparations and diagnostic biomarker reagents for medical purposes, namely, for the diagnosis and/or prognosis of human and/or animal diseases, ailments and/or disorders, in particular bone, sensory organ, virus, urinary tract, kidney, metabolic or central nervous system diseases, ailments and/or disorders and the diagnosis and/or prognosis in relation to complications associated with such diseases, ailments and/or disorders; diagnostic preparations and diagnostic biomarker reagents for medical purposes, namely, for the diagnosis and/or prognosis of diseases, ailments and/or disorders in humans and/or animals, in particular infectious, autoimmune or immunological, cell proliferative and/or oncological diseases, ailments and/or disorders, cancers, tumours and metastases and the diagnosis and/or prognosis in relation to complications associated with such diseases, ailments and/or disorders.
- Class 042 — Scientific and technological services: Scientific services, namely, scientific research in the field of biology, chemistry or medicine, as well as immunology, oncology, molecular biology, cell biology, biochemistry and/or medicinal chemistry, and relating to the discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic agents and diagnostic biomarker reagents and/or diagnostic apparatus; conducting early evaluations in the field of new pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; development of platform technology, namely a cancer immunotherapy platform for the production of therapeutics; chemical, biological and biochemical laboratory services; conducting chemical, biochemical and biological analyses; Medical and scientific research in the field of cancer diagnostics for scientific purposes; Biological and biochemical laboratory; Forensic pathological biological and biochemical examination services; providing technical and scientific research information in the field of biotechnology about a biotechnology company, its technologies, projects, product-candidates, products and/or services via a web site on a global computer network; software design and development; design and development of computer software for use in the fields of biology, chemistry or medicine, in particular immunology, oncology, molecular biology, cellular biology, biochemistry and/or medicinal chemistry, as well as in the fields of discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic preparations and biomarker reagents and/or diagnostic apparatus.
Owner
Prosecution history
- 27 Feb 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 27 Feb 2026 — NON-FINAL ACTION E-MAILED
- 27 Feb 2026 — NON-FINAL ACTION WRITTEN
- 27 Jan 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 27 Jan 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 27 Jan 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 15 Aug 2025 — REFUSAL PROCESSED BY IB
- 29 Jul 2025 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
- 29 Jul 2025 — REFUSAL PROCESSED BY MPU
- 08 Jun 2025 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
- 06 Jun 2025 — NON-FINAL ACTION WRITTEN
- 04 Jun 2025 — ASSIGNED TO EXAMINER
- 21 Mar 2025 — APPLICATION FILING RECEIPT MAILED
- 21 Mar 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 20 Mar 2025 — SN ASSIGNED FOR SECT 66A APPL FROM IB